高精度持续循环腹腔热灌注化疗联合静脉化疗治疗卵巢浆液性囊腺癌的临床研究  

The clinical study of continous hyperthermic peritoneal perfusion chemotherapy combined with intravenous chemotherapy in the treatment of ovary serous cystadenocarcinoma

作　　者：张艳[1] 张菊新[1] 

机构地区：[1]郑州大学人民医院妇产科,郑州450003

出　　处：《现代妇产科进展》2014年第6期436-439,共4页Progress in Obstetrics and Gynecology

基　　金：河南省普通科技攻关项目(No:132102310062)

摘　　要：目的:探讨高精度持续循环腹腔热灌注化疗(CHPPC)联合静脉化疗(IC)对卵巢浆液性囊腺癌满意肿瘤细胞减灭术后患者的疗效及毒副作用。方法:将60例卵巢浆液性囊腺癌满意肿瘤细胞减灭术后患者随机分为实验组和对照组(每组30例),实验组给予CHPPC+IC,对照组给予IC。结果:实验组和对照组中血清CA125半衰期<20天者分别占76.67%、43.33%,差异显著(P<0.05)。按PECIST指南推荐的实体瘤评价标准,实验组和对照组的有效率分别为80.00%和53.33%,差异显著(P<0.05)。实验组和对照组的胃肠道反应发生率分别为96.67%和80.00%,差异显著(P<0.05),余不良反应均无显著差异。随访15个月,实验组和对照组的复发率分别为13.33%和36.67%,生存率分别为90.0%和70.0%,差异均有统计学意义(P<0.05)。结论:CHPPC+IC治疗卵巢浆液性囊腺癌安全、可行、可耐受,能显著提高生存率、减少复发率。Objective： To explore curative effect and side effects of the patients with ovary serous cystadenocarcinoma after satisfied cytoreductive surgery administered by continous hyperthermic peritoneal perfusion chemotherapy（ CHPPC） in combination with intravenous chemotherapy（ IC）. Method： 60 cases of ovarian serous cystadenocarcinoma patients after satisfied cytoreductive surgery were divided into experimental group and the control group（ n = 30）.Experimental group received CHPPC＋IC,and control group only received IC. Results： In experimental group and control group,the serum CA125 half-life 〈20 days respectively taked up76. 67%,43. 33%. And the differences were statistically significant（ P〈0. 05）. According to the evaluation criteria recommended by PECIST,the effective rate of the experimental group and control group were respectively 80. 00%,53. 33%（ P〈0. 05）. For the side effects,the gastrointestinal side effect were respectively 96. 67%,80. 00% in experimental group and the control group（ P〈0. 05）. While other side effects did not have statistically significant（ P〈0. 05）. Followed up for 6 ～ 15 months,recurrence rates of the experimental group and the control group were 13. 33% and 36. 67% respectively. After a follow-up of 15 months,survival rates were90. 0%,70. 0% respectively,and the differences were statistically significant（ P〈0. 05）. Conclusion： CHPPC＋IC is a safe,feasible treatment modality for patients with ovary serous cystadenocarcinoma. It has an acceptable complications rate,ensures a marked improvement in survival and reduces the recurrence rate.

关 键 词：卵巢浆液性囊腺癌 高精度持续循环腹腔热灌注联合静脉化疗 单纯静脉化疗 疗效 毒副作用 

分 类 号：R737.33[医药卫生—肿瘤]